EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY-NC 4.0

Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study

Hongwei Zuo iD, Weisi Dai iD, Jie Mao iD, Mei Ye iD, Xingshan Lu iD, Xiaocui Zhang iD

Therapeutic Apheresis and Dialysis · 2026-12 · 30 (6) · 880-892

DOI: 10.1002/1744-9987.70178 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Therapeutic Apheresis and Dialysis, online erschienen am 30.06.2026. Verfasst von Hongwei Zuo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Chongqing University FuLing Hospital, Chongqing, China. Hauptthemen laut MEDLINE: Kidney Failure, Chronic, Hemodiafiltration, Hemoperfusion, Renal Dialysis. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chongqing Regional Clinical Center for Specific Diseases - Nephrology (Internal Medicine) Establishment Project Fuling District of Chongqing Science and Health….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic micro‐inflammation in patients with end‐stage renal disease (ESRD) is a significant driver of cardiovascular complications and diminished quality of life. While standard hemodialysis (SHD) effectively manages small‐molecule clearance, its ability to remove medium‐to‐large uremic toxins—the primary catalysts of systemic inflammation—remains limited. This study aimed to evaluate the comparative clinical benefits of hemodiafiltration (HDF) and hemoperfusion (HDP) relative to SHD, specifically focusing on inflammatory control, dialysis adequacy, and patient safety.

Methods

This was a 10‐week, single‐center, non‐randomized prospective observational study evaluating 365 end‐stage renal disease (ESRD) patients divided into three cohorts: standard hemodialysis (SHD, n = 145, thrice‐weekly), online hemodiafiltration (HDF, n = 115, twice‐weekly hemodialysis plus once‐weekly HDF), and hemoperfusion (HDP, n = 105, twice‐weekly hemodialysis plus once‐monthly hemoperfusion). Primary endpoints were restricted to short‐term surrogate outcomes, including shifts in serum inflammatory markers (interleukin‐6 (IL‐6), tumor necrosis factor‐alpha (TNF‐ α ), C‐reactive protein (CRP)) and clearance adequacy indices (Kt/V, URR).

Results

Baseline characteristics were well‐balanced across all three cohorts. Following 10 weeks of treatment, the HDF (84.2%) and HDP (77.1%) groups demonstrated significantly higher effective treatment rates (defined by clinical symptom improvement and biochemical stability, a composite of symptomatic improvement and biochemical stability) compared to the SHD group (61.4%; p < 0.05). Advanced modalities achieved increased association with biomarker reduction of middle‐molecule toxins, with HDF showing the most profound reductions in IL‐6, TNF‐ α , and CRP ( p < 0.001). Dialysis adequacy was significantly improved in the HDF group, which showed the highest increases in dialysis adequacy. While the incidence of acute complications such as hypotension and muscle cramps did not differ significantly between groups, both HDF and HDP cohorts reported a notable reduction in post‐dialysis fatigue compared to SHD (14% and 16% vs. 19%, respectively). However, HDF and HDP cohorts experienced lower incidences of cognitive dysfunction.

Conclusions

Over a 10‐week observation framework, advanced hybrid modalities (HDF and HDP) are independently associated with superior clearance of middle‐to‐large molecular uremic toxins and attenuated systemic inflammation compared to SHD. However, these short‐term surrogate improvements did not translate into a statistically significant reduction in clinical adverse events or post‐dialysis fatigue, indicating the need for long‐term longitudinal evaluation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney Failure, ChronicHemodiafiltrationHemoperfusionRenal DialysisInflammationHumansProspective StudiesMaleFemaleMiddle AgedAgedQuality of LifeTreatment OutcomeC-Reactive Protein

Stichwörter der Autor:innen

chronic kidney failurehemodiafiltrationhemodialysishemoperfusionrenal dialysisurea reduction ratiouremia

Substanzen

C-Reactive Protein

Autor:innen und Institutionen

  • Department of Nephrology, Chongqing University FuLing Hospital, Chongqing, China.

ORCID-Profile: Hongwei Zuo, Weisi Dai, Jie Mao, Mei Ye, Xingshan Lu, Xiaocui Zhang

Förderung

  • Chongqing Regional Clinical Center for Specific Diseases - Nephrology (Internal Medicine) Establishment Project Fuling District of Chongqing Science and Health…

Zitieren

APA

Zuo, H., Dai, W., Mao, J., Ye, M., Lu, X., & Zhang, X. (2026). Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study. Therapeutic Apheresis and Dialysis, 30(6), 880-892. https://doi.org/10.1002/1744-9987.70178

Vancouver

Zuo H, Dai W, Mao J, Ye M, Lu X, Zhang X. Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study. Therapeutic Apheresis and Dialysis. 2026;30(6):880-892. doi:10.1002/1744-9987.70178

BibTeX
@article{Zuo2026,
  author = {Zuo, Hongwei and Dai, Weisi and Mao, Jie and Ye, Mei and Lu, Xingshan and Zhang, Xiaocui},
  title = {Comparative Evaluation of Hemodiafiltration, Hemoperfusion, and Standard Hemodialysis on Efficacy, Inflammatory Control, Dialysis Adequacy, and Safety in End‐Stage Renal Disease: A Prospective Observational Study},
  journal = {Therapeutic Apheresis and Dialysis},
  year = {2026},
  volume = {30},
  number = {6},
  pages = {880--892},
  doi = {10.1002/1744-9987.70178}
}
Kostenlos starten →